

Management of Antimicrobial Use in the Intensive Care Unit

Francisco Álvarez-Lerma,¹ Mercedes Palomar² and Santiago Grau¹

1 Hospital del Mar, Barcelona, Spain

2 Hospital Vall d'Hebron, Barcelona, Spain

Contents

Abstract	763
1. Use of Antimicrobials in the Intensive Care Unit (ICU)	764
2. Characteristics of the Use of Antimicrobials in Critically Ill Patients	765
2.1 Collection of Significant Samples of the Infection Foci Before Antimicrobial Administration	765
2.2 Empirical Regimens Using Combinations of or Broad Spectrum Antibacterials.	766
2.3 Use of Maximal Doses	766
2.4 Directed Treatment	767
3. Factors That Influence the Selection of Antimicrobials for Therapeutic Protocols	768
3.1 Pathogens	768
3.2 Antimicrobials	769
3.3 Patients and Infections	770
4. Special Forms of Antimicrobial Administration	770
4.1 Extended-Interval Aminoglycoside Administration	770
4.2 Continuous Infusion of Antibacterials	771
4.3 Local Antibacterial Administration	771
5. Controls During Antimicrobial Therapy	771
5.1 Assessment of Plasma Drug Concentrations	771
5.2 Microbiological Surveillance to Detect the Presence of Resistant Pathogens	772
6. Antimicrobial Policy in the ICU	772

Abstract

Indications for the use of antimicrobials in critically ill patients are similar to those for other hospitalised patients. However, the selection of agents depends on the particular characteristics of patients in the intensive care unit (ICU), the form of presentation of infection, the type of infection and the bacteriological features of the causative pathogens.

The use of antimicrobials in patients admitted to medical-surgical ICUs varies between 33 and 53%. The selection of empirical antimicrobials to be included in treatment protocols of the most common infections depends on the strong inter-relationship between patient characteristics, predominant pathogens in each focus, and antimicrobials used for treatment.

Epidemiological studies carried out in the past have identified the microorganisms most frequently responsible for community-acquired and nosocomial infections in patients admitted to ICUs. Susceptibility to antimicrobial agents may be different between each geographical area, between each hospital and even

within the same hospital service. In addition, susceptibility patterns may change temporarily in relation to the use of particular antimicrobials or in association with other unknown factors so that assessment of endemic antimicrobial resistance patterns is very useful in order to tailor the antimicrobial regimens of therapeutic protocols.

Antimicrobial use should not be a routine procedure. The clinical course of the patient (an indicator of effectiveness) should be closely monitored as well as the possible appearance of adverse effects and/or multiresistant pathogens. Controls are based on the assessment of plasma drug concentrations and microbiological surveillance to detect the presence of multiresistant strains or new antibacterial-resistant pathogens.

Prevention of the development of multiresistant pathogens is the main goal of the ICU antimicrobial policy. Although a series of general strategies to reduce the presence of multiresistant pathogens have been proposed, the implementation of these recommendations in ICUs requires the cooperation of a member of the intensive care team.

Over half of all patients admitted to intensive care units (ICUs) receive one or more antimicrobial agent, and most of these are for the treatment of community-acquired and/or nosocomial infections.^[1-3] Indications for the use of antimicrobials are similar to those for other hospitalised patients, but the selection of agents depends on the particular characteristics of patients in the ICU (severity of illness, immunosuppression, multiorgan failure, high distribution volume), the form of presentation of infections (severe sepsis, septic shock, coagulation disorders, respiratory failure), the type of infection (catheter-related bacteraemia, mechanical ventilation-associated pneumonia), and the bacteriological features of causative pathogens. Numerous studies have confirmed the relationship between antibacterial usage and the development of resistance among both community and hospital bacterial pathogens, as well as for an increased risk of colonisation by hospital pathogens.^[4-9] These phenomena are especially relevant for ICUs, in which the development of nosocomial infection is frequent for different reasons and the presence of multiresistant pathogens may be a determining factor for the outcome of patients.

In most patients, the use of antimicrobials is started before identification of the causative pathogen (empirical treatment). The selection of antimicrobial agents for protocols of empirical treatment

of infections in ICU patients is as a result of careful consideration of the problem taking into account 3 essential elements: pathogens and their susceptibility patterns, antimicrobials and patients.

Between 25 and 50% of antimicrobial prescriptions may be incorrect for reasons of indication, choice, dosage or duration of therapy.^[10,11] Recognition of the consequences of abuse and misuse of antimicrobials prompted the development of a series of guidelines and recommendations to improve antimicrobial usage. Implementation of these recommendations in the ICU setting involves additional difficulties than for other in-patient settings.

The aim of this review is to describe factors of critical importance in the use of antimicrobials in patients hospitalised in the ICU, to discuss how the use of antimicrobials in this patient population can be best managed in the current healthcare environment, and to summarise recommendations based on experts' opinions to improve antimicrobial prescribing patterns.

1. Use of Antimicrobials in the Intensive Care Unit (ICU)

Different multicentre studies carried out in the past have provided data on antibacterial use in ICUs. The European Prevalence of Infection in Intensive Care (EPIC study) showed that 62.3% of patients admitted to the participating ICUs had re-

ceived one or more antibacterial agent on the day of data collection.^[1] A study of the prevalence of nosocomial infection in Spain (EPINE study) revealed that 51% of critically ill patients (including transplant patients) were given antibacterials, which accounted for 5% of the overall antibacterial consumption in the hospital.^[2] According to a national study on surveillance of nosocomial infection in ICU (ENVIN-ICU study) carried out in Spain since 1994 by the Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) working party of infectious diseases, the use of antibacterials in patients admitted to medical-surgical ICUs varied between 33 and 53% (table I).^[3] The severity of the condition of patients admitted to ICUs and their prolonged hospital stay usually determine the prescription of more than one antimicrobial regimen with combinations of different antimicrobials.^[3] The most commonly used agents include broad spectrum antibacterials, particularly third generation cephalosporins, aminoglycosides, broad spectrum penicillins and carbapenems, as well as those antibacterials prescribed for treating multiresistant Gram-positive infections, such as glycopeptides (table II).

2. Characteristics of the Use of Antimicrobials in Critically Ill Patients

In critically ill patients, antimicrobials are prescribed early in the presence of clinical suspicion of an infection process that may have an effect on the patient's final outcome (bacteraemias, pneumonia, meningitis, etc.). In critically ill patients with abdominal infection and ventilator-associated

pneumonia, early administration of adequate antimicrobial cover has been shown to be an independent predictor of outcome.^[12-14]

Infection is suspected on clinical grounds according to detection of clinical signs of a systemic inflammatory response (fever, tachycardia, tachypnoea, chills). These nonspecific signs associated with other signs of focality (crepitation, purulent bronchial secretion, stiffness in the neck, coma, exudate or pus in the catheter insertion site, etc.) allow the selection of the most adequate antimicrobials for each case according to specific therapeutic protocols for each type of infection, which should be adapted to the characteristics of each hospital.

Other patients are given antimicrobial prophylaxis (intravenous, topical) during the postoperative course of different surgical procedures or to prevent infections in extremely severe conditions (transplantation, immunosuppression, polytrauma).

The use of antimicrobials in critically ill patients should follow a series of rules that are common to antimicrobial usage in other hospitalised patients.

2.1 Collection of Significant Samples of the Infection Foci Before Antimicrobial Administration

Starting antimicrobial therapy should be preceded, in all patients, by collection of safety samples (blood, body fluids, exudates, low pulmonary secretions, or other samples that are considered to be appropriate for each focus) using invasive procedures if needed (fiberoptic bronchoscopy, fluoroscopic-guided needle aspiration, etc.). Occasionally, isolation of pathogens in some samples, such

Table I. Antibacterial use in patients admitted to intensive care units (ICUs) [ENVIN-ICU Study, 1994-1998]^[3]

Year	No. of patients	Patients receiving antibacterials (%)	No. of antibacterials given	Antibacterials/patients receiving antibacterials
1994	1884	877 (46.5)	1864	2.13
1995	1794	603 (33.6)	1299	2.15
1996	7151	3817 (53.4)	8114	2.13
1997	2393	1121 (46.8)	2485	2.22
1998	3909	2033 (52.0)	3921	1.93
Total	17 131	8451 (49.3)	17 683	2.09

Table II. Changes in antibacterial use in patients admitted to intensive care units (ICUs) [ENVIN-ICU Study, 1994-1998]^[3]

Data	1994 (%)	1995 (%)	1996 (%)	1997 (%)	1998 (%)
Patients receiving antibiotics	877	603	3817	1121	2033
Cephalosporins	566 (64.5)	351 (58.2)	2528 (66.2)	694 (61.9)	1086 (53.4)
first generation	164 (18.7)	100 (16.6)	776 (20.3)	202 (18.0)	285 (14.0)
second generation	110 (12.5)	73 (12.1)	428 (11.2)	103 (9.2)	175 (8.6)
third generation	292 (33.3)	178 (28.7)	1306 (34.2)	364 (32.5)	554 (27.3)
fourth generation			18 (0.5)	25 (2.2)	72 (3.6)
Aminoglycosides	280 (31.9)	212 (35.2)	1206 (31.6)	372 (33.2)	525 (25.8)
Penicillins ^a	189 (21.6)	122 (20.2)	771 (20.2)	294 (26.2)	510 (25.1)
Quinolones	97 (11.1)	72 (12.3)	392 (10.3)	114 (10.2)	187 (9.2)
Glycopeptides	139 (15.8)	72 (11.9)	755 (19.8)	222 (19.8)	351 (17.3)
Carbapenems	96 (10.9)	81 (13.4)	626 (16.4)	192 (17.1)	263 (12.9)
Macrolides	50 (5.7)	39 (6.5)	328 (8.6)	93 (8.3)	114 (5.6)
Penicillins	127 (14.5)	167 (27.7)	339 (8.9)	90 (8.0)	178 (8.8)
Metronidazole	66 (7.5)	41 (6.8)	307 (8.6)	107 (9.5)	184 (9.1)

a Broad spectrum.

as bronchial secretions, urine or drainage fluid, do not confirm the presence of infection (it may only indicate colonisation) and, in these situations, the relationship of these findings with the patient's clinical manifestations should be evaluated. In other situations, isolation of pathogens allows the aetiology of infection to be established and, in some clinical situations (e.g. bacteraemia, pneumonia, meningitis), the confirmation of the presence of infection (i.e. a definitive diagnosis).

2.2 Empirical Regimens Using Combinations of Broad Spectrum Antibacterials.

Empirical treatment with broad spectrum bactericidal agents, and frequently with combinations of these agents to increase the therapeutic range or the bactericidal action, is based on initial severity of the patient's condition, additional infection-attributed mortality, time delay in the availability of results of bacteriological studies, and the low sensitivity and/or specificity of some diagnostic methods. Antibacterials should be administered by the intravenous route to quickly obtain a high plasma and tissue drug concentrations. Some authors believe that early use of adequate empirical antibacterials is the most important factor for a fa-

vourable evolution in patients with pneumonitis or peritonitis.

2.3 Use of Maximal Doses

The first dose of antimicrobial should be the maximal dose followed by doses adjusted to the patient's hepatic and renal function. The goal is to attain maximal plasma concentrations (C_{max}) several times higher than minimal inhibitory concentration (MIC) of the causative pathogen ($C_{max} : MIC$ ratio). Other pharmacodynamic parameters include the area under the concentration time curve (AUC) : MIC ratio and the time interval in which plasma drug concentrations are greater than the MIC.^[15] The 2 first parameters, $C_{max} : MIC$ ratio and AUC : MIC ratio, are used for antibacterials whose bactericidal activity depends on maximal concentration, such as the aminoglycosides and quinolones,^[16,17] whereas the third pharmacodynamic parameter is used for time-dependent killing agents, such as the β -lactams.^[18] The use of low or subclinical doses has been related to the selection of multiresistant bacteria.

Table III shows maximal doses of 29 antibacterials and 4 antifungal agents most frequently used in patients in the ICU together with dose adjustments based on creatinine clearance values.

Table III. Dosages of 29 antibacterial and 4 antifungal agents most frequently used in intensive care units (ICUs) and doses adjusted to renal function

Antimicrobial	Creatinine clearance			
	>80 ml/min	80-50 ml/min	50-10 ml/min	<10 ml/min
Cefazolin	0.5-2g/8h	0.5-2g/8h	1g/12h	1g/24h
Cefotaxime	2-3g/6-8h	1-2g/6-8h	1-2g/8h	1-2g/24h
Vancomycin	15-25 mg/kg/12h	1g/24h	1g/3-5 days	1g/7 days
Imipenem/cilastin	0.5-1g/6-8h	0.5-1g/8h	0.5-1g/12h	0.5-1g/24h
Amoxicillin/clavulanic acid	1-2g/100-200mg/6-8h	1-2g/100-200mg/6-8h	1-2g/100-200 mg/12h	1-2g/100-200mg/24h
Amikacin	15 mg/kg/24h	15 mg/kg/24h	4-12 mg/kg/24h	2-4 mg/kg/24h
Tobramycin	3-5 mg/kg/24h	3-5 mg/kg/24h	1-3 mg/kg/24h	0.5-1 mg/kg/24h
Gentamicin	3-5 mg/kg/24h	3-5 mg/kg/24h	1-3 mg/kg/24h	0.5-1 mg/kg/24h
Ciprofloxacin	200-400mg/8-12h	200-400mg/8-12h	200-400mg/8-12h	250-500mg/12h
Ceftazidime	1-2g/8-12h	1-2g/8-12h	1g/12-24h	0.5g/24h
Erythromycin	30-50 mg/kg/24h	30-50 mg/kg/24h	30-50 mg/kg/24h	30-50 mg/kg/24h
Cefuroxime	0.75-1g/8h	0.75-1g/8h	750mg/12h	750mg/24h
Metronidazole	250-750 mg/6h	250-750mg/6h	250-750mg/6h	250-750mg/6h
Ceftriaxone	2-4 g/24h	1-2g/24h	1-2g/24h	0.5-1g/24h
Piperacillin/tazobactam	4g/0.5 g/6h	4g/0.5g/6h	4g/0.5g/8h	4g/0.5g/12h
Clindamycin	300-900 mg/6-8h	300-900mg/6-8h	300-900mg/6-8h	300-900mg/6-8h
Aztreonam	1-2g/8-12h	1-2g/8-12h	0.5-1g/8-12h	1g/24h
Cloxacillin	1-3g/4-6h	1-3g/4-6h	1-3g/4-6h	0.5-2g/6-8h
Ampicillin	1-2g/4-6h	1-2g/4-6h	1-2g/6-8h	1-2g/12h
Teicoplanin ^a	12 mg/kg/24h	6 mg/kg/24h	6 mg/kg/48h	6 mg/kg/72h
Penicillin sodium	1-3 mol/L/2-4h	1-3mol/L/2-4h	1-3mol/L/8h	1-2mol/L/12h
Cotrimoxazole	160-800mg/8-12h	160-800mg/8-12h	160-800mg/8-12h	80-400mg/24h
Meropenem	1-2g/8-12h	1-2g/8-12h	0.5-1g/8-12h	1g/24h
Rifampin ^b	10 mg/kg/24h	10 mg/kg/24h	10 mg/kg/24h	10 mg/kg/24h
Cefoxitin	1-2g/4-6h	1-2g/4-6h	1-2g/12-24h	0.5-1g/12-24h
Cefonicid	1-2g/24h	1-2g/24h	1g/48h	1-3g/5 days
Piperacillin	4g/6h	4g/6h	4g/8h	4g/12h
Ofloxacin	200-400mg/12h	200-400mg/12h	200-400mg/12h	200mg/12h
Cefepime	1-2g/8-12h	1-2g/8-12h	2g/24h	0.5-1g/24h
Fluconazole	400-800mg/24h	400-800mg/24h	200-400mg/24h	200mg/24h
Amphotericin B				
deoxycholate	0.3-1.5 mg/kg/24-48h	0.3-1.5 mg/kg/24-48h	0.3-1.5 mg/kg/24-48h	0.3-1.5 mg/kg/24-48h
lipid complex	3-5 mg/kg/24h	3-5 mg/kg/24h	3-5 mg/kg/24h	3-5 mg/kg/24h
liposomal	1-3 mg/kg/24h	1-3 mg/kg/24h	1-3 mg/kg/24h	1-3 mg/kg/24h

a The first 3 doses every 12 hours.

b Maximum 600mg if bodyweight >50kg and 450mg if bodyweight <50kg.

2.4 Directed Treatment

Antimicrobial treatment should be adjusted after identification of the causative pathogen. Antibacterials more active against the isolated pathogens, with better tissue penetration, which are less toxic and with the most reduced bactericidal spectrum should be selected even in patients with fa-

vourable clinical evolution. First-choice antimicrobials for treating the most frequently isolated causative pathogens of ICU infections, as well as those to be used in cases of multiresistance, are shown in table IV. A single antimicrobial can be used in the majority of cases (monotherapy), except for pathogens frequently associated with the rapid development of resistance during treatment

Table IV. First-line antimicrobials for treating the most common infections in patients in the intensive care unit (ICU)

First choice	Multiresistance
<i>Pseudomonas aeruginosa</i>	
Ceftazidime	Colistin
Cefepime	
Piperacillin/tazobactam	
Imipenem/cilastin	
Meropenem	
Aztreonam	
Amikacin	
Ciprofloxacin	
<i>Staphylococcus aureus</i>	
Cloxacillin ^b	Vancomycin
First generation cephalosporins	Teicoplanin Quinupristin-dalfopristin Linezolid
<i>Acinetobacter baumannii</i>	
Piperacillin/tazobactam	Ampicillin/sulbactam
Imipenem/cilastin	Doxycycline
Meropenem	Colistin
Amikacin	
Tobramycin	
<i>Enterococcus faecalis</i>	
Amoxicillin	Vancomycin
Ampicillin	Teicoplanin
Gentamicin ^a	Quinupristin-dalfopristin
Piperacillin	Linezolid
<i>Staphylococcus epidermidis</i>	
Vancomycin	Quinupristin-dalfopristin
Teicoplanin	Linezolid
Cloxacillin ^b	
<i>Escherichia coli</i>	
Second, third, fourth generation cephalosporins	Imipenem/cilastin Meropenem
Amoxicillin/clavulanic acid	
Piperacillin/tazobactam	
Ciprofloxacin	
Aminoglycoside	
<i>Candida albicans</i>	
Fluconazole	
Amphotericin B	
<i>Haemophilus influenzae</i>	
Amoxicillin/clavulanic acid	Imipenem/cilastin
Second, third generation cephalosporins	Meropenem
Aztreonam	

a In gentamicin-susceptible strains.

b In cloxacillin-susceptible strains.

or with relapses, and/or pathogens associated with poor prognosis, such as infections caused by *Pseudomonas aeruginosa*.^[19-21] The use of 2 or more antimicrobials is recommended in these situations, although no study has demonstrated that combined treatments are more effective.

3. Factors That Influence the Selection of Antimicrobials for Therapeutic Protocols

The selection of empirical antimicrobials to be included in treatment protocols of the most common infections depends on the strong inter-relationship between patient characteristics, predominant pathogens in each focus, and antimicrobials used for treatment (fig. 1). Although no study has been designed to specifically address the impact of appropriate empirical therapy on the clinical course of an infection process, different studies have provided evidence for a poor prognosis in patients treated inappropriately.^[12-14,22-24]

3.1 Pathogens

Epidemiological studies carried out in the past have identified the micro-organisms most frequently responsible for community-acquired and nosocomial infections in patients in the ICU, ^[2,11,25-28] as well as the evolution of their antimicrobial susceptibility patterns. These data are useful for selecting those antimicrobial agents which are most appropriate for the treatment of each type of infection. Moreover, it would be useful to have information on the distribution of pathogens in the hospitals through the development of a sequential epidemiological map in which the incidence of the most frequent infections as well as the incidence of the corresponding causative pathogens will be included.

This distribution of nosocomial infections in the ICU varies largely from nosocomial infections in other hospitalised patients, with mechanical ventilation-associated pneumonia, urethral catheter-related urinary tract infection, and catheter-related bacteraemia being the most prevalent. The most frequent causative pathogens for each type of in-




Fig. 1. Relationship between patient characteristics, causative micro-organisms and antimicrobials.

fection in the ENVIN-ICU study^[25] are listed in table V.

Susceptibility to antimicrobial agents may be different between each geographical area, between each hospital and even within the same hospital service. In addition, susceptibility patterns may change temporarily in relation to the use of particular antimicrobials or in association with other unknown factors.^[29] This means that assessment of endemic antimicrobial resistance patterns is very useful to tailor the antimicrobial regimens of therapeutic protocols. Personnel responsible for epidemiological surveillance should be alert to the detection of cross-resistance among Gram-negative rods or multiresistance in a particular strain. In these situations, some authors^[30,31] have proposed control of the endogenous flora of the patients at risk (bronchial aspirates in mechanically ventilated patients, samples from the oropharynx and rectum in patients with long hospital stay and burn patients, etc.) should be obtained for an early detection of dissemination of the multiresistant strain and to change (if appropriate) the antimicrobials included in empirical therapeutic protocols.

Whenever susceptibility to different antimicrobials is maintained by endemic strains predominating in the hospital service, it would be possible to make an alternative selection, which in turn would prevent the development of new resistance mechanisms by the repeated use of one of them. A progressive increase in the emergence of resistance to

a particular agent or to a class of agents should cause temporary discontinuation of its use in both empirical and directed regimens.

3.2 Antimicrobials

Physicians who prescribe antimicrobials should be aware of the main pharmacological characteristics of those agents most commonly administered, including the range of antimicrobial activity, pharmacokinetics, important adverse effects, mechanism of action, clinically relevant interactions, and clinical effectiveness in different indications. The lack of information on some of these aspects may have a negative influence on clinical response to some antimicrobials, such as:

- limited ability to attain adequate concentrations in the affected tissue (vancomycin in the cerebrospinal fluid, aminoglycosides in bronchial secretions and pancreatic tissue)^[32-34]
- possibility of inactivation by acidic pH (aminoglycosides, imipenem/cilastatin)^[35]
- differences in the post-antibiotic effect (minimal for β -lactams and very high for aminoglycosides).^[36]

Table V. Aetiological agents for the main nosocomial infections in patients in the intensive care unit (ICU) from the ENVIN-ICU Study, (1994-1998)^[25]

Type of infection	Cases (%)
Mechanical ventilation-associated pneumonia	
<i>Pseudomonas aeruginosa</i>	24-36
<i>Staphylococcus aureus</i>	18-19
<i>Acinetobacter</i> spp.	10-18
<i>Escherichia coli</i>	3-11
<i>Haemophilus influenzae</i>	2-11
Urethral catheter-associated urinary tract infection	
<i>E. coli</i>	25-32
<i>Candida</i> spp.	17-21
<i>Enterococcus</i> spp.	10-22
<i>P. aeruginosa</i>	10-11
Vascular catheter-related primary bacteremia	
<i>Streptococcus epidermidis</i>	26-35
<i>Enterococcus</i> spp.	5-21
<i>Candida</i> spp.	3-21
<i>P. aeruginosa</i>	2-12
<i>S. aureus</i>	2-7

3.3 Patients and Infections

The characteristics of the patient are the essential factors in determining the causative pathogen. The aetiology of an infection depends on a number of factors, in particular, the immunological status of the patient, which has been associated with some disorders (haematological and oncological diseases, organ transplantation, HIV infection) or some treatments (chemotherapy, corticosteroids). Treatment of opportunistic pathogens frequently found in these patients (fungi, viruses, mycobacteria) should also be considered in protocols of empirical antimicrobial use.

In immunocompetent patients, factors influencing the selection of pathogens are those capable of modifying the primary endogenous flora which predominates in mucous membranes of healthy individuals. Antimicrobial use, prolonged stay in hospital and alteration of natural defensive barriers resulting from insertion of urethral catheters, tracheal tubes or intravascular devices, configures clearly differentiated risk groups. Accordingly, in the group of patients 'without risk factors', causative pathogens are predominantly micro-organisms of the primary endogenous flora present at the time of hospital or ICU admission (*Streptococcus pneumoniae*, methicillin-susceptible *Staphylococcus aureus*, *Haemophilus influenzae*, and Enterobacteriaceae of the digestive tract). These are previously healthy patients admitted to the hospital because of acute conditions (trauma, neurological or surgical) without previous antimicrobial exposure, who develop an infection a few days after hospital admission (primary endogenous infection). Empirical treatment should include the use of antimicrobials that are effective against primary endogenous flora (table VI).

In another group of patients, infections are caused by secondary endogenous flora in which pathogens forming part of the ecosystem of the hospital, with a different distribution in each centre. In the ICUs, this secondary endogenous flora includes *P. aeruginosa*, *Acinetobacter baumannii*, and intestinal Enterobacteriaceae (table VI). Other pathogens, such as methicillin-resistant *S. aureus* (MRSA),

extended-spectrum β -lactamase (ESBL) resistance noted predominantly in *Klebsiella pneumoniae*, or *Stenotrophomonas maltophilia* that may initially colonise patients at risk and be the cause of new infections, may appear occasionally in a particular area. These are patients admitted to the hospital for many days with different previous antimicrobial regimens with broad spectrum agents and mucosal instrumentation in whom empirical antimicrobials included in therapeutic protocols should be effective against the most prevalent pathogens for a given time at each care area of the critically ill patient.

4. Special Forms of Antimicrobial Administration

4.1 Extended-Interval Aminoglycoside Administration

Single daily doses of aminoglycosides have been recommended in recent years.^[37,38] The bactericidal activity of these agents is dose-dependent, with a $C_{max} : MIC$ ratio >10 for the optimal dose.^[39] This regimen is associated with a C_{max} and a greater

Table VI. Predominant micro-organisms in patients with intensive care unit (ICU)-acquired nosocomial infection according to epidemiological surveillance studies at ICU admission

Type of infection	Pathogens micro-organisms
Primary endogenous (previous colonisation at ICU admission)	<i>Streptococcus pneumoniae</i>
	<i>Haemophilus influenzae</i>
	<i>Escherichia coli</i>
	Methicillin-sensitive <i>Staphylococcus aureus</i>
	<i>Moraxella catarrhalis</i>
Secondary endogenous (not present at ICU admission)	<i>Klebsiella</i> spp.
	<i>Proteus</i> spp.
	<i>Enterobacter</i> spp.
	<i>Serratia</i> spp.
	<i>Pseudomonas</i> spp.
	<i>Stenotrophomonas maltophilia</i>
Exogenous (external reservoir)	Methicillin-resistant <i>S. aureus</i>
	<i>Candida</i> spp.
	<i>Salmonella</i> spp. (enteral nutrition)
	<i>Burkholderia cepacea</i> (pressure cuffs)
	<i>Acinetobacter baumannii</i> (respirators)

post-antibiotic effect and has shown a similar efficacy to that of multiple-dose regimens. Two recent meta-analyses^[40,41] that included 14 and 21 random studies, respectively, have shown a decrease in nephrotoxicity between 13 and 25% with the use of the extended-interval aminoglycoside dosing (EIAD) regimen. Differences in relation to ototoxicity have not been clearly established. In patients with enterococcal endocarditis, renal insufficiency, and impaired distribution volume, there is insufficient evidence to recommend the use of EIAD.^[42] Information on the use of EIAD in pregnant women is not available.

4.2 Continuous Infusion of Antibacterials

Potential advantages of continuous infusion of antibacterials are based on experimental studies with β -lactams especially ceftazidime^[43,44] and cefepime.^[45] *In vitro*, β -lactams have shown a time-dependent killing effect. Experience with this modality of antibacterial administration is limited and refers to treatment of *P. aeruginosa* infection in patients with neutropenia or cystic fibrosis.^[46-48] Moreover, there are clinical experiences with the administration of vancomycin^[49,50] and flucloxacillin^[51] in the treatment of severe infections caused by Gram-positive bacteria.

However, future clinical data will contribute to better define its indication in critically ill patients in whom antibacterial regimens with intermittent doses would have been unsuccessful or in clinical conditions in which concentrations above MIC for most of the administration interval is required.

4.3 Local Antibacterial Administration

The use of multiple combinations of antibacterials may occasionally be unsuccessful in patients with severe infection. In these cases, the presence of multiresistant pathogens makes it necessary to achieve maximal antibacterial concentrations at the site of infection. Although aminoglycosides usually have *in vitro* activity against these bacteria, their clinical efficacy is limited by poor penetration at the site of infection, especially in bronchial secretions and pulmonary parenchyma. Local ad-

ministration of antibacterials in the airways to increase antibacterial concentration at the focus of infection has been proposed.^[52]

In a double-blind, randomised, placebo-controlled multicentre study, Brown et al.^[53] reported no significant differences in the clinical response of bacterial pneumonia, although in the group in which tobramycin was instilled endotracheally, a greater frequency of eradication of the causative pathogens of the pneumonia was achieved. In a non-comparative study, Stoutenbeek et al.^[54] achieved excellent results with aerosolised antibacterials (tobramycin plus cefotaxime or ceftazidime) in association with the same antibacterials given intravenously in patients with severe pneumonia who had previously received antibacterials by the gastrointestinal route.

At the present time, evidence of the efficacy of topical administration of antibacterials is limited, but it may be possible that in the future this modality of treatment may be selected in patients with poor prognosis (immunosuppressed, APACHE score >20) or in case of infection caused by high risk pathogens (multiresistant *P. aeruginosa* and *A. baumannii*).

5. Controls During Antimicrobial Therapy

Antimicrobial use should not be a routine procedure. The clinical course of the patient (an indicator of efficacy) should be closely monitored in addition to the possible appearance of adverse effects and/or multiresistant pathogens. Controls for antimicrobial use are based on the following criteria.

5.1 Assessment of Plasma Drug Concentrations

Pharmacokinetics of antimicrobial drugs in ICU patients may be altered as a result of haemodynamic changes, renal and/or hepatic failure, generalised oedema, increased volume of distribution, and other complications. Therefore, there is a large between-individual variability in plasma drug concentrations when the same doses are given, so that

antimicrobial doses should be optimised, particularly in drugs with a narrow therapeutic range, such as aminoglycosides and vancomycin.^[55]

The implementation of pharmacokinetic programmes specifically designed for the therapeutic monitoring of antimicrobial agents, allows dose requirements to be estimated to obtain maximal clinical efficacy with a minimal incidence of adverse effects.^[56]

5.2 Microbiological Surveillance to Detect the Presence of Resistant Pathogens

The high level of use of antimicrobial agents in ICUs favours the appearance of multiresistant pathogens, the presence of which is associated with both failure of antimicrobial therapy in a given patient and selection of a multiresistant endogenous flora that will influence antibacterial policy of that ICU in the future.

In the critically ill patient, isolation of multiresistant pathogens may occur in the following circumstances:^[57]

- individual isolation in a patient at risk (prolonged ICU stay, previous use of various combinations of broad spectrum antibacterials, high severity score). In this situation, multiresistant strains, such as MRSA, *S. maltophilia*, *P. aeruginosa*, *Candida albicans* or other species of fungi, are frequently identified in the last phase of the clinical course of the patient. The presence of these pathogens is a marker of severity, although it has a low effect on the final outcome for the patient or on the antibiotic policy of the ICU
- isolation of one or more resistant strains of the same species in the form of an epidemic outbreak (*A. baumannii*, *K. pneumoniae* containing ESBL, *E. faecium*, MRSA). As these strains form part of the environment of the ICU, patients are colonised rapidly, independently of their degree of severity. This form of presentation has an important impact on the antibiotic policy of the ICU and a major effect on the clinical course of patients with intermediate degrees of illness severity

- detection of resistance of the original strain, particularly during treatment with cephalosporins, in relation to the development of antibacterial-induced inactivating enzymes (β -lactamases), especially in the case of Enterobacteriaceae and *P. aeruginosa*. This event is associated with failure of antimicrobial therapy and an increase in mortality. In the case of persistence, it is necessary to restrict the use of third generation cephalosporins. The importance of these multiresistant pathogens varies between different countries, whereas vancomycin-resistant *Enterococcus* spp. (VRE) are mainly responsible for outbreaks in ICUs in the US. Enterobacteriaceae containing ESBL and *A. baumannii* are particularly frequent in European ICUs.

6. Antimicrobial Policy in the ICU

Prevention of the development of multiresistant pathogens is the main goal of the antimicrobial policy of an ICU. Although a series of general strategies to reduce the presence of multiresistant pathogens have been proposed,^[58,59] the implementation of these recommendations in ICUs requires the cooperation of a member of the intensive care team who is an expert in infection diseases. Recommendations allowing for better use of antimicrobials in ICUs^[60] are shown in table VII.

Antimicrobial policy in ICUs is based on the preparation and implementation of protocols for different types of infections in the critically ill patient. All specialists involved in the prevention and treatment of infections should participate in the development of guidelines, although the intensive care specialist should be responsible for implementing recommendations and for auditing the fulfillment of guidelines in daily practice.

Information generated by Services of Clinical Microbiology is the basis of directed therapy and the cornerstone of empirical therapy. Early awareness of pathogens responsible for a particular infection and/or their susceptibility patterns allows and facilitates the use of antimicrobials in a directed manner. Moreover, protocols of empirical therapy should be modified according to periodical infor-

Table VII. Recommendations for optimising the use of antimicrobials in the intensive care unit (ICU)

Antimicrobials should be used only when there is clinical and/or microbiological suspicion of infection
Samples of infected tissues should be obtained prior to initiating antimicrobial therapy
Empirical antimicrobials should be selected according to therapeutic protocols developed by consensus
A rapid result from the laboratory of microbiology should be pursued
A directed treatment should be selected when the aetiology of infection is known
The effectiveness of treatment should be monitored
The development of adverse effects and/or emerging multiresistant flora should be controlled
Duration of treatment should be limited according to the clinical and/or microbiological response
An intensive care physician should be responsible for the control and treatment of infections
Medical staff should be aware of the need for and fulfillment of antimicrobial policy guidelines

mation of pathogens that predominate most significantly in recovered samples and the results of susceptibility testing. Collaboration with the ICU can be enhanced by holding joint meetings presenting data on changes of infection indicators and resistance markers, and discussing therapeutic strategies in relation to the development of multiresistant strains. Some hospitals have available 'guidelines for the use of antimicrobial agents' with information on rational use of antimicrobials for each type of prophylaxis or infection reached by consensus. Intensive care physicians responsible for control and surveillance of infections and the use of antimicrobials should participate in the preparation of therapeutic protocols for the most frequent infections seen in the ICU.^[61]

Restrictive policies in the area of antimicrobial use vary from strict prohibition of the use of a particular antimicrobial to the requirement of a written justification for the use of some antimicrobials or of a previous consultation with an expert. These policies, widely implemented in some countries, are associated with a low level of adherence among physicians and an excessive amount of bureaucracy that in the ICUs may lead to nonadherence to

guidelines or to a lack of rigorousness in the information requested.^[62]

The development of computer-assisted management programs for antimicrobial use has given a great impulse to the rational control of antimicrobials and to the possibility of eliminating restrictive strategies.^[63,64] However, despite these programmes, good communication with staff responsible for infectious diseases in each hospital service, especially with those in ICUs, ensures not only a correct use of antimicrobial agents but also the introduction of early changes when incorrect antimicrobial regimens are detected.

Acknowledgements

We thank Marta Pulido, MD, for editing the manuscript and editorial assistance.

References

1. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. *JAMA* 1995; 274: 639-44
2. Vaque J, Rossello J, Trilla A, et al. Nosocomial infections in Spain: results of 5 nationwide serial prevalence surveys (EPINE Project, 1990 to 1994). *Infect Control Hosp Epidemiol* 1996; 17: 293-7
3. Insausti J, Alvarez-Lerma F, de la Cal MA, et al. Antibiotic usage patterns and trends in Spanish Intensive Care Unit (ICUs) [abstract]. *Intensive Care Med* 1997; 23 Suppl. 1: S110
4. Feeley TW, du Moulin GC, Hedley-Whyte J, et al. Aerosol polymyxin and pneumonia in serious ill patients. *N Engl J Med* 1975; 293: 471-5
5. Gaman W, Cates C, Snelling CF, et al. Emergence of gentamicin- and carbenicillin-resistant *Pseudomonas aeruginosa* in a hospital environment. *Antimicrob Agents Chemother* 1976; 9: 474-80
6. Vogel F, Knothe H. Changes in aerobic faecal bacterial flora of severely ill patients during antibiotic treatment. *Klin Wochenschr* 1985; 63: 1174-9
7. Dworzack DL, Pugsley MP, Sanders CC, et al. Emergence of resistance in Gram-negative bacteria during therapy with extended-spectrum cephalosporins. *Eur J Clin Microbiol* 1987; 6: 456-9
8. Webb CH. Antibiotic resistance associated with selective decontamination of the digestive tract [editorial]. *J Hosp Infect* 1992; 22: 1-5
9. Nardi G, Valentini U, Proietti A, et al. Epidemiological impact of prolonged systematic use of topical SDD on bacterial colonization of the tracheobronchial tree and antibiotic resistance. A 3 year study. *Intensive Care Med* 1993; 19: 273-8
10. Kunin CM. Problems in antibiotic usage. In: Mandell GL, Douglas RG, Bennet JE, editors. *Principles and practice of infectious diseases*. New York: Churchill Livingstone, 1990; 427-33

11. Roder BL, Nielsen SL, Magnussen P, et al. Antibiotic usage in an intensive care unit in a Danish university hospital. *J Antimicrob Chemother* 1993; 32: 633-42
12. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. *Ann Surg* 1991; 214: 543-9
13. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. *Chest* 1997; 111: 676-85
14. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest* 1999; 115: 462-74
15. Polk R. Optimal use of modern antibiotics: emerging trends. *Clin Infect Dis* 1999; 29: 264-74
16. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. *Clin Infect Dis* 1998; 27: 23-7
17. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against *Streptococcus pneumoniae* in an *in vitro* model of infection. *Antimicrob Agents Chemother* 1999; 43: 672-7
18. Turnidge JD. The pharmacodynamics of beta-lactams. *Clin Infect Dis* 1998; 27: 10-22
19. Fink MP, Snyderman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with impipenem-cilastatin. The Severe Pneumonia Study Group. *Antimicrob Agents Chemother* 1994; 38: 547-57
20. Silver DR, Cohen IL, Weinberg PF. Recurrent *Pseudomonas aeruginosa* pneumonia in a intensive care unit. *Chest* 1992; 101: 194-8
21. Crouch Brewer S, Wunderink RG, Jones CB, et al. Ventilator-associated pneumonia due to *Pseudomonas aeruginosa*. *Chest* 1996; 109: 1019-29
22. Torres A, Aznar R, Gatell JM, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. *Am Rev Respir Dis* 1990; 142: 523-8
23. Alvarez-Lerma F, ICU-Acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. *Intensive Care Med* 1996; 22: 387-94
24. Barriere SL, Lowry SF. An overview of mortality risk prediction in sepsis. *Crit Care Med* 1995; 23: 376-93
25. Palomar M, Alvarez-Lerma F, de la Cal MA, et al. ICU infections in Spain. Time trends of etiology and resistances from 1994 to 1998 [abstract]. *Intensive Care Med* 1999; 25: 163
26. Rello J, Rodriguez R, Jubert P, et al. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. *Clin Infect Dis* 1996; 23: 723-8
27. Valles J, Leon C, Alvarez-Lerma F, et al. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. *Clin Infect Dis* 1997; 24: 387-95
28. Alvarez-Lerma F, Palomar M, Martinez-Pellus A, et al. Etiology and diagnostic techniques in Intensive care acquired pneumonia. *Clin Intensive Care* 1997; 8: 164-70
29. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant *Pseudomonas aeruginosa*: comparison of risk associated with different antipseudomonal agents. *Antimicrob Agents Chemother* 1999; 43: 1379-82
30. Damjanovic V, van Saene HKF. The value of surveillance cultures in neonatal intensive care units. In: van Saene HKF, Silvestri L, de la Cal MA, editors. *Infection control in the intensive care unit*. Berlin: Springer-Verlag, 1998; 316-22
31. van Saene HKF, Damjanovic V, Silvestri L, et al. Classification on infections. In: van Saene HKF, Silvestri L, de la Cal MA, editors. *Infection control in the intensive care unit*. Berlin: Springer-Verlag, 1998; 17-28
32. Viladrich PF, Gudiol F, Linares J, et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. *Antimicrob Agents Chemother* 1991; 35: 2467-72
33. Pennington JE. Penetration of antibiotics into respiratory secretions. *Rev Infect Dis* 1981; 3: 67-73
34. Büchler M, Malfertheiner P, Friess H, et al. Human pancreatic tissue concentration of bactericidal antibiotics. *Gastroenterology* 1992; 103: 1902-8
35. Pelaez T, Bouza E. Actividad antianaerobica de los carbapenemicos. *Enferm Infecc Microbiol Clin* 1997; 15 Suppl. 1: 8-13
36. Pruell H, McDonald PJ. Damage to bacteria by antibiotics *in vitro* and its relevance to antimicrobial chemotherapy: a historical perspective. *J Antimicrob Chemother* 1988; 21: 695-8
37. ter Braak EW, de Vries PJ, Bouter KP, et al. Once daily dosing regimen for aminoglycoside plus betalactam combination therapy of serious infections: comparative trial with netilmicin plus ceftriaxone. *Am J Med* 1990; 89: 58-66
38. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. *Lancet* 1993; 341: 335-9
39. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adults patients. *Antimicrob Agents Chemother* 1995; 39: 650-5
40. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. *Ann Intern Med* 1996; 124: 717-25
41. Barza M, Ioannidis JPA, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. *BMJ* 1996; 312: 338-44
42. Rodvold KA, Danziger LH, Quinn JP. Single daily doses of aminoglycosides. *Lancet* 1997; 350: 1412
43. Visser LG, Arnouts P, van Furth R, et al. Clinical pharmacokinetics of continuous intravenous administration of penicillins. *Clin Infect Dis* 1993; 17: 491-5
44. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. *Clin Pharmacokinet* 1995; 28: 143-60
45. Tessier PR, Nicolau DP, Onyeji CD, et al. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against *Pseudomonas aeruginosa* in an *in vitro* infection model. *Chemotherapy* 1999; 45: 284-95
46. Daenen S, de Vries-Hospers H. Cure of *Pseudomonas aeruginosa* infection in neutropenic patients by continuous infusion of ceftazidime [letter]. *Lancet* 1988; 1: 937
47. Vinks AAT, Touw DJ, Heijerman HGM, et al. Pharmacokinetics of ceftazidime in adult cystic fibrosis during continuous infusion and ambulatory treatment at home. *Ther Drug Monit* 1994; 16: 341-8
48. Daenen S, Erjavec Z, Uges DR, et al. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. *Eur J Clin Microb Infect Dis* 1995; 14: 188-92
49. Di Filippo A, DE Gaudio AR, Novelli A, et al. Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. *Chemotherapy* 1998; 44: 63-8
50. James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-pos-

- itive infections. *Antimicrob Agents Chemother* 1996; 40: 696-700
51. Leder K, Turnidge JD, Korman TM, et al. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. *J Antimicrob Chemother* 1999; 43: 113-8
52. Makhoul IR, Mezbach D, Lichtig C, et al. Antibiotic treatment of experimental *Pseudomonas aeruginosa* pneumonia in guinea pigs: comparison of aerosol and systemic administration. *J Infect Dis* 1993; 168: 1296-9
53. Brown RB, Kruse JA, Counts GW, et al. Double-blind study of endotracheal tobramycin in the treatment of Gram-negative bacterial pneumonia. *Antimicrob Agents Chemother* 1990; 34: 269-72
54. Stoutenbeek CP, van Saene HKF, Miranda DR, et al. Nosocomial gram-negative pneumonia in critically ill patients. A 3-year experience with a novel therapeutic regimen. *Intensive Care Med* 1986; 12: 419-23
55. Begg EJ, Barclay ML, Kirkpatrick CJM. The therapeutic monitoring of antimicrobial agents. *Br J Clin Pharmacol* 1999; 47: 23-30
56. Slattery JT. A pharmacokinetic model-independent approach for estimating dose required to give derived steady-state trough concentrations of drug in plasma. *J Pharmacokinetics Biopharm* 1980; 8: 105-10
57. Alvarez Lerma F. Impacto de las resistencias bacterianas sobre la política antibiótica. *Med Intensiva* 1998; 22: 17-23
58. Yates RR. New intervention strategies for reducing antibiotic resistance. *Chest* 1999; 115: 24S-7S
59. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. *Chest* 1999; 115: 19S-23S
60. Alvarez Lerma F, Palomar Martínez M. Decalogo de normas para la utilización de antibióticos en pacientes críticos. *Med Intensiva* 2000; 24: 69-77
61. Drobnic L, Grau S, Salas E, et al. Guía terapéutica antimicrobiana, 1995. Madrid. Consorci Sanitari de Barcelona. IMAS, 1995
62. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow practice guidelines? A framework for improvement. *JAMA* 1999; 282: 1458-65.
63. Grau S, Monterde J, Carmona A, et al. Monitoring of antimicrobial therapy by an integrated computer program. *Pharm World Sci* 1999; 21: 152-7
64. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other anti-infective agents. *N Engl J Med* 1998; 338: 232-8

Correspondence and offprints: Dr *Francisco Álvarez-Lerma*, Servicio de Medicina Intensiva, Hospital del Mar, Passeig Marítim 25-29, E-08003 Barcelona, Spain.
E-mail: 16839@imas.imim.es